Study of an oral drug for hospitalized COVID-19 patients
Part of Infections, Lungs & breathing clinical trials.
This trial tests an oral drug called SPI-1005 for people hospitalized with moderate COVID-19. The drug may help reduce inflammation and protect the lungs, and the study will compare it to a placebo (a pill with no active medicine) to see if it helps people recover.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have a positive COVID-19 test (from a swab or saliva sample)
- You must be sick enough to be in the hospital but not needing high-flow oxygen or a ventilator
- Your moderate symptoms must have started within 3 days of joining the study
- You must not be pregnant or breastfeeding, and you must have no major liver or kidney problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an antiviral medicine called FS-1 (brand name Efesovir) in adults hospitalized with COVID-19 who have risk factors for severe illness. The goal is to see if the drug can help them recover faster or avoid more serious complications.
This early-stage study tests COVID-19 treatments in people who have recently developed symptoms and who test positive for the virus. It aims to find safer, more effective options for preventing worsening disease, especially in higher-risk groups.
This trial tests a drug called AVM0703 to see if it can help people with severe lung damage caused by COVID-19 or influenza. It focuses on patients who need a breathing machine or ECMO because their lungs are failing.
This early-phase trial tests a new drug (called B10-FC) to see if it's safe and how the body processes it. It is given once to healthy adults, and later to people with mild or moderate COVID-19 who are at higher risk of getting very sick.
This trial tests whether Codivir can help people hospitalized with moderate COVID-19 recover better than a placebo (inactive pill). It will compare outcomes while participants receive standard hospital care.
This trial tests a medicine called Sonlicromanol to see if it helps people with lingering symptoms after a mild case of COVID-19. It is for people who have post-exertional malaise (feeling very tired or worse after activity) and a moderate level of disability.
Hear when a new Covid19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.